Liver injury in COVID-19: The current evidence
- PMID: 32450787
- PMCID: PMC7268949
- DOI: 10.1177/2050640620924157
Liver injury in COVID-19: The current evidence
Abstract
Patients with novel coronavirus disease 2019 (COVID-19) experience various degrees of liver function abnormalities. Liver injury requires extensive work-up and continuous surveillance and can be multifactorial and heterogeneous in nature. In the context of COVID-19, clinicians will have to determine whether liver injury is related to an underlying liver disease, drugs used for the treatment of COVID-19, direct effect of the virus, or a complicated disease course. Recent studies proposed several theories on potential mechanisms of liver injury in these patients. This review summarizes current evidence related to hepatobiliary complications in COVID-19, provides an overview of the available case series and critically elucidates the proposed mechanisms and provides recommendations for clinicians.
Keywords: COVID-19; SARS-CoV2; cholangiocytes; cytokine storm; liver function test; liver injury; lymphopenia.
Figures
References
-
- Yang Z, Xu M, Yi JQ, et al. Clinical characteristics and mechanism of liver damage in patients with severe acute respiratory syndrome. Hepatobiliary Pancreat Dis Int 2005; 4: 60–63. - PubMed
-
- Liu F, Long X, Zou W, et al. Highly ACE2 expression in pancreas may cause pancreas damage after SARS-CoV-2 infection. medrxiv Preprint 3 March 2020: 2020.2002. 2028.20029181. DOI: 10.1101/2020.02.28.20029181.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous